Articles related to BIOMARKERS

Discover the implications of a newly identified depression subtype, “cognitive biotype,” which not only presents with significant cognitive impairments but also shows resistance to standard antidepressant treatments.

Explore the complexities of treating small cell lung cancer (SCLC) after platinum-based therapy failure, including insights into immune checkpoint inhibitors, the preference for lurbinectedin, and the potential of liquid biopsies. Join Dr. Misty Shields in understanding the challenges and opportunities in this evolving field.

Physicians, take note: as scientific understanding of the genetics of aging deepens, potential interventions for age-related diseases may be on the horizon. Keep abreast of this promising field to better guide your patients towards healthy aging.

This is a golden opportunity to bolster your understanding of AML, implement novel diagnostic strategies, and integrate state-of-the-art treatment plans into your practice. Enrich your professional knowledge, earn valuable CME credits, and most importantly, help improve the lives of your patients.

Unveiling fresh perspectives on dry eye disease treatment through a comprehensive study that scrutinizes tear proteomic analysis and clinical parameters. In a breakthrough study on dry eye disease (DED) treatment, researchers employed tear proteomic analysis to identify potential tear biomarkers. They combined this with a rigorous examination of clinical parameters. Data was gathered from a double-blinded, national multicenter clinical trial involving 80 DED patients. The subjects underwent treatment with either 0.1% cyclosporine, 0.05% cyclosporine, or 3% diquafosol eye drops. Observations took place at four-week intervals, lasting for 12 weeks. Key metrics observed included tear break-up time, corneal erosion, conjunctival erosion, and symptom assessment in dry eye scores. This data was then correlated with protein expressions identified through the proteomic analysis. Interestingly, the same seven proteins were identified in all treatment groups. These proteins were noted to be downregulated following treatment. At the 12-week mark, all clinical parameters demonstrated a significant improvement from the baseline. However, among the groups, no significant differences in values were recorded, except in the case of corneal erosion. The latter parameter significantly improved after treatment with both cyclosporine concentrations, as compared to the diquafosol group. However, the correlation of these proteins with the clinical parameters was […]

This study presents findings from a Phase I clinical trial examining the use of Stereotactic Body Radiotherapy (SBRT) combined with pembrolizumab (P) in treating advanced solid tumors, with a focus on the safety and effectiveness of partial tumor irradiation. The trial involved 97 patients, 47% of whom received at least one partial radiation treatment. The overall one-year local failure (LF) rate was 7.6%, and the results suggest an association between tumor response to SBRT+P and improved overall survival (OS), particularly for irradiated tumors. The trial also explored the role of biomarkers, finding that a high Radiomics Score (RS), based largely on CD8+ T cell levels, was linked to better LF, progression-free survival (PFS), and OS. Conversely, increased levels of circulating cytokine IL-8 were associated with worse PFS and OS. The study concluded that SBRT+P is safe for patients with large, advanced solid tumors and recommended further research to compare the effectiveness of complete versus partial tumor irradiation in the context of immunotherapy.